Title
Overrepresentation of Injection Drug Use Route of Infection Among Human Immunodeficiency Virus Long-term Nonprogressors: A Nationwide, Retrospective Cohort Study in China, 1989-2016.

Permalink
https://escholarship.org/uc/item/6j30216g

Journal
Open forum infectious diseases, 6(5)

ISSN
2328-8957

Authors
Han, Jing
Wu, Zunyou
McGoogan, Jennifer M
et al

Publication Date
2019-05-01

DOI
10.1093/ofid/ofz182

Peer reviewed
Overrepresentation of Injection Drug Use Route of Infection Among Human Immunodeficiency Virus Long-term Nonprogressors: A Nationwide, Retrospective Cohort Study in China, 1989–2016

Jing Han, Zunyou Wu, Jennifer M. McGoogan, Yurong Mao, Houlin Tang, Jian Li, Yan Zhao, Cong Jin, Roger Detels, Ron Brookmeyer, Viviane D. Lima, and Julio S. G. Montaner

1National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China; Departments of 2Epidemiology and 3Biostatistics, Fielding School of Public Health, University of California–Los Angeles; 4British Columbia Centre for Excellence in HIV/AIDS, University of British Columbia, Vancouver, Canada

Background. Why some persons living with human immunodeficiency virus (HIV) (PLWH) progress quickly and others remain “healthy” for a decade or more without treatment remains a fundamental question of HIV pathology. We aimed to assess the epidemiological characteristics of HIV long-term nonprogressors (LTNPs) based on a cohort of PLWH in China observed between 1989 and 2016.

Methods. We conducted a nationwide, retrospective cohort study among Chinese PLWH with HIV diagnosed before 1 January 2008. Records were extracted from China's national HIV/AIDS database on 30 June 2016. LTNPs were defined as those with AIDS-free, antiretroviral therapy–naive survival, with CD4 cell counts consistently ≥500/μL for ≥8 years after diagnosis. Prevalence was calculated, characteristics were described, and determinants were assessed by means of logistic regression. Potential sources of bias were also investigated.

Results. Our cohort included 89,201 participants, of whom 1,749 (2.0%) were categorized as LTNPs. The injection drug use (IDU) route of infection was reported by 70.7% of LTNPs, compared with only 37.1% of non-LTNPs. The odds of LTNP status were greater among those infected via IDU (adjusted odds ratio [95% confidence interval], 2.28 [1.94–2.68]) and with HIV diagnosed in settings with large populations of persons who inject drugs (1.75 [1.51–2.02] for detention centers, 1.61 [1.39–1.87] for Yunnan, 1.94 [1.62–2.31] for Guangdong, and 2.90 [2.09–4.02] for Xinjiang).

Conclusions. Overrepresentation of the IDU route of infection among LTNPs is a surprising finding worthy of further study, and this newly defined cohort may be particularly well suited to exploration of the molecular biological mechanisms underlying HIV long-term nonprogression.

Keywords. CD4 cell count; HIV slow progression; injection drug use; long-term nonprogression; opioids.
National HIV/AIDS Comprehensive Response Information Management System (CRIMS), which has tracked every individual with a diagnosis of HIV infection in the entire country since 1985 [19].

METHODS
Design and Setting
We conducted a nationwide, retrospective cohort study in China to investigate long-term nonprogression of HIV disease among Chinese persons with HIV diagnosed before 1 January 2008. Data were extracted on 30 June 2016, so all participants were followed up for ≥8 years. None were excluded owing to loss to follow-up. Rather, all meeting study eligibility criteria were included regardless of the duration since the most recent follow-up visit. Figure 1 shows the design of our study.

Data Source
We used data extracted from CRIMS, a real-time, web-based information system managed by the National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention. As described elsewhere [19], CRIMS contains records for all individuals with an HIV diagnosis in China; there are no missing or duplicate cases because reporting is mandatory and records are linked to national identification numbers. Records contain contact and demographic information, testing and baseline clinical information, patient-reported route of infection, dates and details of all follow-up visits, and other health-related information (e.g., coinfections and comorbid conditions), as well as dates and causes of death. However, CRIMS does have some important limitations that must be noted. For example, CRIMS records do not contain estimated dates of infection or seroconversion. Therefore, PLWH often have already had HIV infection for some years at the time of diagnosis. Indeed, a recent study in China found a median duration of infection of 6.3 years before diagnosis [20]. This means that, in China, an individual with CD4 cell counts consistently ≥500/μL without ART for >8 years, has probably been infected for even longer and remained “healthy.” Moreover, it was common during our study period for persons with newly diagnosed HIV with CD4 cell counts above the 200/μL, 350/μL, and 500/μL thresholds to remain untreated for some time [21]. Although clinical guidelines specified that CD4 cell count should be evaluated annually regardless of treatment status [22], this evaluation has been inconsistent and infrequent in practice, resulting in many CRIMS records containing few CD4 cell count results. Finally, clinical guidelines in China do not allow viral load (VL) testing until ≥6 months after ART initiation and only annually thereafter [22]. Hence, no VL data are available for any patient before ART initiation, and—as with CD4 cell counts—VL testing has been inconsistent and infrequent, and records contain few results. Moreover, aside from rare drug resistance test results, viral subtype and sequence data are not available.

Figure 1. Development of the study cohort. All persons living with human immunodeficiency virus (HIV) in China who had a date of HIV diagnosis before 1 January 2008 were screened for study eligibility. A total of 89,201 (59.1%) were included in the analysis and categorized by their long-term nonprogressor (LTNP) status. A total of 1,749 LTNP s were found, for a prevalence of 2.0%. All 89,201 study participants were followed up until records were extracted on 30 June 2016, for ≥8 years or until death. To investigate potential lead-time bias caused by earlier diagnosis in some individuals than in others, a subanalysis was conducted among only those in the cohort with baseline CD4 cell counts ≥500/μL.
Cohort Development

Development of the study cohort is shown in Figure 1. All CRIMS records with a date of HIV diagnosis before 1 January 2008 were screened for study eligibility. Two inclusion criteria were applied: ≥15 years of age at HIV diagnosis (ie, age cutoff for adulthood according to China’s HIV clinical guidelines [22]) and CD4 cell counts. Records were excluded if they did not contain enough information to categorize participants by LTNP status. All eligible records were extracted on 30 June 2016, which was 8 years after the latest possible diagnosis date.

Development of the Study Definition of LTNP

Although a recent systematic review by Gurdasani et al [5] found 159 unique definitions of HIV LTNP in the literature, the common theme was that LTNPs remain asymptomatic with no AIDS-defining illness for a prolonged time (ie, the period of nonprogression) while retaining a high CD4 cell count (ie, the CD4 cell count threshold) in the absence of ART, although LTNPs may start ART or develop symptoms, progress to AIDS, or die after the period of nonprogression has been completed and still be considered LTNPs. However, the length of the nonprogression period and the level of the CD4 cell count threshold vary, and our data source has some important limitations that required consideration.

We examined definitions used in similar published studies. For example, Madec et al [7] used >8 years with CD4 cell counts >500/μL and Grabar et al [10] used ≥8 years with CD4 cell counts ≥500/μL, whereas Okulicz et al [8] used both ≥7 years and ≥10 years with CD4 cell counts ≥500/μL, and Mandalia et al [9] used ≥7 years and the stability of the slope of multiple CD4 cell counts. Most definitions captured in the review by Gurdasani et al [5] used a 10-year nonprogression period and a CD4 cell count threshold of 500/μL. Therefore, we too selected the ≥500/μL threshold but chose a somewhat shorter ≥8-year nonprogression period for our study, because HIV in China is often diagnosed late, a median of 6.3 years after infection [20].

We then put this into context with the data we had available to us in CRIMS, thereby defining the 2 major components of our LTNP definition. The first was duration of nonprogression ≥8 years. To meet this criterion, CRIMS records were required to demonstrate a ≥8-year survival period after the date of diagnosis (which was before 1 January 2008) with (1) no HIV/AIDS symptoms or AIDS-defining illness and (2) no ART. After 8 years, evidence of ART, symptoms, AIDS, or death did not cause records to be excluded from categorization as LTNPs.

The second component was CD4 cell count ≥500/μL. To meet this criterion, CRIMS records were required to contain (1) ≥2 CD4 cell counts ≥500/μL and none <500/μL during the ≥8-year nonprogression period after the date of diagnosis, (2) ≥1 CD4 cell count ≥500/μL after the ≥8-year nonprogression period was completed, and (3) a ≥1-year time interval between first ever and last (or most recent) CD4 cell count ≥500/μL.

To illustrate this definition, we present 7 hypothetical scenarios in Figure 2. Scenarios 1–4 describe generalized patients categorized as non-LTNPs for failure to meet ≥1 component of the LTNP study definition. Scenarios 5–7 illustrate generalized patients categorized as LTNPs. Because scenarios 1–4 (non-LTNPs) may have had a smaller chance of being categorized as LTNPs simply owing to later diagnosis, we also investigated the possibility of lead-time bias in our cohort.

---

**Figure 2.** Illustration of the study definition of long-term nonprogressors (LTNPs). Abbreviation: ART, antiretroviral therapy.
Data Analysis

Categorical variables are presented as numbers and percentages, and prevalence comparisons were conducted using \( \chi^2 \) test, with 1 category for each variable used as a reference. Continuous variables are presented as median with interquartile range (IQR) but not compared for statistical test. Missing data were categorized as unknown but still included in the analyses. Observed time was calculated from the date of diagnosis to study end or death and expressed in person-years (PYs). Factors associated with LTNP status were investigated using univariable and multivariable logistic regression with results reported as odds ratios and 95% confidence intervals (CIs). Because of potential for lead-time bias—participants with HIV diagnosed earlier may have had a greater chance of being categorized as LTNP—we repeated the logistic regression analysis using only the subset of participants with baseline CD4 cell counts \( \geq 500/\mu L \). In addition, because of the potential for confounding bias owing to some key variables being related, we conducted 4 crossover stratified analyses using binary logistic regression, with LTNP status as the dichotomous dependent variable. All analyses were conducted using SPSS software (version 24.0; IBM).

Ethics

The protocol was approved by the institutional review board of the National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention. Informed consent was not required because all individuals with HIV diagnosed in China sign written informed consent at diagnosis, allowing future use of their deidentified data for epidemiological studies.

RESULTS

As shown in Figure 1, a total of 171 833 CRIMS records were screened, and a total of 89 201 (51.9%) participants were included in our cohort. Among the 82 632 who were excluded, 10 447 (12.6%) were <15 years of age, 71 294 (86.3%) lacked CD4 cell count results, and 891 (1.1%) had insufficient information in their records to categorize them as LTNP or non-LTNPs.

Characteristics of study participants are presented in Table 1. At baseline (diagnosis), most participants were aged 25–34 years (43.6%) or 25–34 years (42.3%), male (68.0%), of Han ethnicity (73.8%), and married (52.6%). A majority had junior high school education or less (junior high, 43.4%, primary school or less, 40.8%) and worked as farmers (54.4%). The most frequent HIV infection routes were injection drug use (IDU; 37.8%) and heterosexual contact (33.4%). Most have HIV diagnosed at voluntary counseling and testing locations (28.6%) or detention centers (23.0%), in Yunnan (24.9%) or Henan (20.4%), and between 2005 and 2008 (70.3%). Most had baseline CD4 cell counts <500/μL (≤199/μL, 32.0%; 200–349/μL, 25.1%; 350–499/μL, 21.5%).

A total of 1749 participants (of 89 201) met the definition of LTNP, for an overall, nationwide LTNP prevalence of 2.0%. The prevalence of LTNP status was higher among those who were aged 15–24 (3.8%) or 25–34 (2.5%) years, male (2.4%), ethnic Uygur (5.1%), never married (3.1%), and had homemaker/unemployed (3.0%) or service industry worker (2.9%) as their occupation. LTNP status was also more prevalent among participants with an IDU infection route (3.7%) and diabetes in detention centers (4.0%), in Yunnan (2.5%), Guangdong (3.9%), and Xinjiang (5.0%), and in the 1990–2004 period (3.3%). The median (IQR) observed time for non-LTNPs was 8.8 (7.1–10.7) PYs and for LTNPs was a higher but comparable 11.0 (9.7–13.0) PYs (Table 1).

Results of our investigation into factors associated with LTNP status are presented in Table 2. After adjustment for confounding, we found greater odds of LTNP status among participants who were younger (adjusted odds ratio [AOR] [95% CI] vs age ≥25 years, 1.90 [1.66–2.17] for age 25–34 years and 3.34 [2.87–3.88] for age 15–24 years), had an IDU route of infection (vs heterosexual contact, 2.28 [1.94–2.68]), had HIV diagnosed in a detention center (vs a voluntary counseling and testing location, 1.75 [1.51–2.02]), a blood donation station (1.84 [1.41–2.39]), or as a part of a special investigation (1.61 [1.32–1.96]), and in Yunnan (vs other provinces, 1.61 [1.39–1.87]), Guangxi (1.46 [1.21–1.77]), Guangdong (1.94 [1.62–2.31]), or Xinjiang (2.90 [2.09–4.02]). The odds of LTNP status were lower for those of minority ethnicities other than Uygur (AOR [95% CI] vs Han, 0.66 [0.57–0.76]) and for those with heterosexual contact as their infection route (vs heterosexual contact, 0.45 [0.25–0.80]). When diagnosis location was left out of the model, the odds of LTNP status were greater for those of Uygur ethnicity (AOR [95% CI] vs Han, 1.84 [1.59–2.12]).

Results of the subanalysis that included only participants with baseline CD4 cell counts ≥500/μL are presented in Table 3. After adjusting for confounding, we found greater odds of LTNP status among those who were younger (AOR [95% CI], 1.56 [1.36–1.79] for age 25–34 years and 2.28 [1.94–2.67] for age 15–24 years), had IDU (2.12 [1.79–2.50]) or blood products (1.61 [1.14–2.28]) as their infection route, had HIV diagnosed in a detention center (1.60 [1.38–1.86]), in a blood donation station (1.66 [1.26–2.19]), or as a part of a special investigation (1.52 [1.24–1.88]), and in Yunnan (1.52 [1.31–1.78]), Guangxi (2.05 [1.68–2.49]), Guangdong (2.26 [1.87–2.73]), or Xinjiang (2.95 [2.08–4.18]). The odds of LTNP status were lower among other ethnicities (AOR [95% CI], 0.60 [0.52–0.70]) and those with homosexual contact as the infection route (0.45 [0.25–0.80]). When diagnosis location was left out of the model, the odds of LTNP status among those who reported their route of infection as blood products was no longer significantly elevated (AOR [95% CI], 0.91 [0.71–1.17]).

Results of binary logistic regression analyses are presented in Tables 4–7. Among those with Uygur ethnicity, those with an IDU infection route had greater odds of LTNP status (AOR [95% CI], 2.18 [1.58–3.03]). However, among those with all other
Table 1. Characteristics of Study Participants in the Nationwide Cohort (China, 1989–2016) and Prevalence of Long-term Nonprogressor (LTNP) and Non-LTNP Status

| Characteristic                         | All Participants, No. (Column %) | Participants, No. (Row %) | P Value  |
|----------------------------------------|----------------------------------|---------------------------|----------|
| Total sample                           | 89,201 (100.0)                  | 87,452 (98.0)             | 1,749 (2.0) | ...
| Baseline characteristics               |                                  |                           |          |
| Age group, y                           |                                  |                           |          |
| ≥35                                    | 37,750 (42.3)                   | 37,416 (99.1)             | 334 (0.9) | (Ref) |
| 25–34                                  | 38,933 (43.6)                   | 37,997 (97.6)             | 936 (2.5) | <.001 |
| 15–24                                  | 12,518 (14.0)                   | 12,039 (96.2)             | 479 (3.8) | <.001 |
| Sex                                    |                                  |                           |          |
| Female                                 | 28,523 (32.0)                   | 28,195 (98.9)             | 328 (1.1) | (Ref) |
| Male                                   | 60,678 (68.0)                   | 59,257 (97.7)             | 1,421 (2.4) | <.001 |
| Ethnicity                              |                                  |                           |          |
| Han                                    | 65,849 (73.8)                   | 64,693 (98.2)             | 1,156 (1.8) | (Ref) |
| Uygur                                  | 5319 (6.0)                      | 5048 (94.9)               | 271 (5.1) | <.001 |
| Other                                  | 15,741 (17.6)                   | 15,476 (98.3)             | 265 (1.7) | .5 |
| Unknown                                | 2,292 (2.6)                     | 2,235 (97.5)              | 57 (2.5) | <.001 |
| Marital status                         |                                  |                           |          |
| Married                                | 46,943 (52.6)                   | 46,340 (98.7)             | 603 (1.3) | (Ref) |
| Never married                          | 22,405 (25.1)                   | 21,713 (96.9)             | 692 (3.1) | <.001 |
| Divorced/widowed                       | 17,686 (19.8)                   | 17,332 (98.0)             | 354 (2.0) | <.001 |
| Unknown                                | 2,167 (2.4)                     | 2,067 (95.4)              | 100 (4.6) | <.001 |
| Education                              |                                  |                           |          |
| Primary school or less                 | 36,352 (40.8)                   | 35,698 (98.2)             | 654 (1.8) | (Ref) |
| Junior high school                     | 38,754 (43.4)                   | 37,921 (97.9)             | 833 (2.1) | <.001 |
| Senior high school or more             | 10,836 (12.1)                   | 10,681 (98.6)             | 155 (1.4) | .01 |
| Unknown                                | 3,259 (3.7)                     | 3,152 (96.7)              | 107 (3.3) | <.001 |
| Occupation                             |                                  |                           |          |
| Farmer                                 | 48,521 (54.4)                   | 47,836 (98.6)             | 685 (1.4) | (Ref) |
| Homemaker/unemployed                   | 18,108 (20.3)                   | 17,563 (97.0)             | 545 (3.0) | <.001 |
| Service industry worker                | 4,237 (4.7)                     | 4,114 (97.1)              | 123 (2.9) | <.001 |
| Laborer                                | 3,910 (4.4)                     | 3,825 (97.8)              | 85 (2.2) | <.001 |
| Government employee                    | 3,056 (3.4)                     | 3,025 (99.9)              | 31 (1.0) | .07 |
| Other                                  | 6,457 (7.2)                     | 6,229 (98.0)              | 128 (2.0) | <.001 |
| Unknown                                | 4,912 (5.5)                     | 4,760 (96.9)              | 152 (3.1) | <.001 |
| Route of infection                     |                                  |                           |          |
| Heterosexual contact                   | 29,809 (33.4)                   | 29,518 (99.0)             | 291 (1.0) | (Ref) |
| Injection drug use                     | 33,715 (37.8)                   | 32,476 (96.3)             | 1,237 (3.7) | <.001 |
| Blood products*                        | 19,626 (22.0)                   | 19,484 (99.3)             | 142 (0.7) | .003 |
| Homosexual contact                     | 2,572 (2.9)                     | 2,559 (99.5)              | 13 (0.5) | .02 |
| Unknown                                | 3,479 (3.9)                     | 3,413 (98.1)              | 66 (1.9) | <.001 |
| Type of diagnosis site                 |                                  |                           |          |
| VCT location                           | 25,540 (28.6)                   | 25,219 (98.7)             | 321 (1.3) | (Ref) |
| Detention center                       | 20,511 (23.0)                   | 19,690 (96.0)             | 821 (4.0) | .03 |
| Hospital/clinic                        | 16,067 (18.0)                   | 15,903 (99.0)             | 164 (1.0) | <.001 |
| Blood donation station                 | 8,474 (9.5)                     | 8,382 (98.9)              | 92 (1.1) | .21 |
| Investigation                          | 7,795 (8.7)                     | 7,635 (97.9)              | 160 (2.1) | <.001 |
| Spouse/sex partner test                | 4,278 (4.8)                     | 4,239 (99.1)              | 39 (0.9) | .06 |
| Other†                                 | 6,536 (7.3)                     | 6,384 (97.7)              | 152 (2.3) | <.001 |
| Location of diagnosis site             |                                  |                           |          |
| Other‡                                 | 24,656 (27.6)                   | 24,352 (98.8)             | 304 (1.2) | (Ref) |
| Yunnan                                 | 22,246 (24.9)                   | 21,700 (97.5)             | 546 (2.5) | <.001 |
| Henan                                  | 18,165 (20.4)                   | 18,036 (99.3)             | 129 (0.7) | <.001 |
| Guangxi                                | 11,334 (12.7)                   | 11,130 (98.2)             | 204 (1.8) | <.001 |
| Guangdong                              | 6,587 (7.4)                     | 6,330 (96.1)              | 257 (3.9) | <.001 |
| Xinjiang                               | 6,213 (7.0)                     | 5,904 (95.0)              | 309 (5.0) | <.001 |
ethnicities, those with IDU infection route also had greater odds of LTNP status (AOR [95% CI], 3.97 [3.45–4.57]; Table 4). Among those with an IDU infection route, those of Uygur ethnicity had greater odds of LTNP status (AOR [95% CI], 1.75 [1.50–2.04]), and among those with other infection routes, those of Uygur ethnicity also had greater odds of LTNP status (3.44 [2.55–4.66]) (Table 5). Among participants in all 3 age groups, those with IDU infection route had greater odds of LTNP status (AOR [95% CI], 3.64 [2.90–4.57] for age 15–24 years, 3.33 [2.77–4.01] for age 25–34 years, and 4.26 [3.17–5.74] for age ≥35 years), as did those of Uygur ethnicity (2.19 [1.72–6.77] for age 15–24 years, 2.23 [1.86–2.69] for age 25–34 years, and 3.25 [2.23–4.75] for age ≥35 years) (Table 6). Finally, among participants with HIV diagnosed in 1990–2004 or in 2005–2008, the odds of LTNP status were greater among those with an IDU infection route (AOR [95% CI], 3.27 [2.54–4.22] for diagnosis in 1990–2004 and 2.85 [2.44–3.33] for diagnosis in 2005–2008) and those of Uygur ethnicity (5.33 [4.40–6.46] for diagnosis in 1990–2004 and 2.28 [1.87–2.78] for diagnosis in 2005–2008) (Table 7).

**DISCUSSION**

The present study represents the first-ever establishment of a large nationwide cohort of LTNP in China—an ethnically diverse middle-income country where HIV genetic diversity is substantial [18]. We found that persons who reported their route of infection as IDU were overrepresented among this Chinese LTNP cohort at 70.7% (1237 of 1749), compared with 37.3% (32 478 of 87 452) among non-LTNPs. In multivariable analyses, the IDU infection route was associated with >2-fold higher odds of LTNP status. Moreover, HIV diagnosis in settings where persons who inject drugs (PWID) were more concentrated—detention centers [23], and Yunnan, Guangxi, Guangdong, or Xinjiang provinces [24]—was also associated with greater odds of LTNP status.

These results were unexpected, because an extensive literature documents epidemiological, clinical, in vivo, and in vitro evidence of opioids acting as an accelerator of HIV pathogenesis owing to negative effects on host immune function [25–32]. We found only 1 small study in Sweden documenting slower HIV disease progression among PWID [33]. A more recent, larger study in Hubei, China, found similar results [34]. However, in both studies, the comparison group was not non-PWID. Rather, it was men who have sex with men (MSM) [33, 34]. In China, where non-B subtype viral strains are dominant, different subtypes and circulating recombinant forms (CRFs; eg, CRF01_AE, CRF07_BC, and CRF08_BC) are known to vary in prevalence among the different key populations owing

| Characteristic            | All Participants, No. (Column %)* | Participants, No. (Row %)* | Non-LTNPs | LTNP | PValue^b |
|---------------------------|-----------------------------------|-----------------------------|-----------|------|---------|
| Year of diagnosis         |                                   |                             |           |      |         |
| 1990–2004                 | 26 464 (29.7)                     | 25 584 (96.7)               | 880 (3.3) |      | ...     |
| 2005–2008                 | 62 737 (70.3)                     | 61 868 (98.6)               | 869 (1.4) |      | <.001   |
| Baseline CD4 cell count   |                                   |                             |           |      |         |
| ≤199/μL                   | 28 559 (32.0)                     | 28 559 (100)                | 0 (0.0)   |      |         |
| 200–349/μL                | 22 393 (26.1)                     | 22 393 (100)                | 0 (0.0)   |      |         |
| 350–499/μL                | 19 165 (21.5)                     | 19 165 (100)                | 0 (0.0)   |      |         |
| ≥500/μL                   | 19 084 (21.4)                     | 17 335 (90.8)               | 1749 (9.2) |      |         |
| Median (IQR), cells/μL   | 306 (152–468)                     | 301 (149–456)               | 738 (611–896) |      |         |
| Follow-up characteristics |                                   |                             |           |      |         |
| Observation time, PYs     |                                   |                             |           |      |         |
| All participants          |                                   |                             |           |      |         |
| Median (IQR)              | 8.9 (7.2–10.7)                    | 8.8 (7.1–10.7)              | 11.0 (9.7–13.0) |      | ...     |
| Range                     | 0.1–26.5                          | 0.1–26.5                    | 8.0–23.6  |      | ...     |
| Participants with baseline CD4 cell count ≥500/μL | 9.0 (7.9–10.8) | 8.9 (7.8–10.5) | 11.0 (9.7–13.0) |      | ...     |
| Range                     | 0.1–23.6                          | 0.1–20.0                    | 8.0–23.6  |      | ...     |
| Median participant CD4 cell count, cells/μL | 289 (151–430) | 284 (147–420) | 732 (612–826) |      | ...     |
| Range                     | 2–1980                            | 2–1980                      | 504–1670  |      |         |

Abbreviations: IQR, interquartile range; LTNPs, long-term nonprogressors; PYs, person-years; Ref, reference category; VCT, voluntary counseling and testing.

aData represent no. (%) of participants unless otherwise specified.

^bCategorical variables were compared between categories using χ^2 tests.

^cThe “Other” category for the ethnicity variable includes the remaining 49 minority ethnicities recognized by the Chinese Government.

^dThe “Other” category for the occupation variable includes all other occupations as well as students.

^eThe “Blood products” category encompasses infection via either blood product donation or receipt.

^fThe “Other” category for the type of diagnosis site variable includes enlisted physical, exit and entry physical, premarital, occupational exposure, and entertainment place examinations.

^gThe “Other” category for the location of diagnosis site variable includes the remaining 27 provinces in China.
to their relative abundance in sexual and needle-sharing networks [35–38]. Thus, it is possible that our finding of over-representation of the IDU infection route among LTNPs in China may be related to viral genetic factors. This idea is further bolstered by the observation that MSM had lower odds of being LTNPs.

We found that LTNPs in our cohort were roughly 80% more likely to have been diagnosed in a detention center, and 50%–190% more likely to have had HIV diagnosed in Yunnan, Guangxi, Guangdong, and Xinjiang. These findings make sense in the China context, because confinement of drug users in detention centers has been common practice for several decades [39], and because China’s HIV epidemic among drug users is well known to have originated in Yunnan and expanded over drug trafficking routes to Guangxi, Guangdong, and Xinjiang [24]. Recent HIV genomic studies have revealed the chronology and geography of the spread of unique variants of the virus that mirror the expansion of China’s HIV epidemic among drug users and are distinct from HIV genetic variants more common in other risk groups (eg, MSM) [35–38]. We believe that these findings also suggest the influence of viral factors in our cohort that require further investigation.

In the present study, we have largely focused on a first-time, epidemiological characterization of this cohort. To this end, we have found, for example, that younger age and Uygur ethnicity were associated with greater odds of LTNP status, whereas other minority groups had lesser odds. Although 1 study in the United States has found an association between LTNP status and ethnicity [8], other studies have found no such association [4, 9, 13]. The notable association between Uygur ethnicity and greater odds of LTNP status may be

Table 2. Factors Associated with Long-term Nonprogressor Status: Results of Univariable and Multivariable Logistic Regression Analyses in a Nationwide Cohort (China, 1989–2016)

| Variable                      | Odds Ratio (95% Confidence Interval) | Unadjusted | Adjusteda | Adjustedb |
|-------------------------------|--------------------------------------|------------|-----------|-----------|
| Age group, y                  |                                      |            |           |           |
| ≥35                           | 1.00                                 | 1.00       | 1.00      |           |
| 25–34                         | 2.76 (2.43–3.13)                     | 1.94 (1.70–2.21) | 1.90 (1.68–2.17) |
| 15–24                         | 4.46 (3.87–5.13)                     | 3.38 (2.91–3.93) | 3.34 (2.87–3.88) |
| Sex                           |                                      |            |           |           |
| Female                        | 1.00                                 | 1.00       | 1.00      |           |
| Male                          | 2.06 (1.83–2.33)                     | 1.26 (1.10–1.44) | 1.23 (1.07–1.41) |
| Ethnicity                     |                                      |            |           |           |
| Han                           | 1.00                                 | 1.00       | 1.00      |           |
| Uygur                         | 3.00 (2.62–3.44)                     | 1.84 (1.59–2.12) | 0.97 (0.70–1.34) |
| Other                         | 0.96 (0.84–1.10)                     | 0.64 (0.56–0.74) | 0.66 (0.57–0.76) |
| Unknown                       | 1.43 (1.09–1.87)                     | 1.25 (1.09–1.72) | 1.16 (1.03–1.62) |
| Route of infection            |                                      |            |           |           |
| Heterosexual contact          | 1.00                                 | 1.00       | 1.00      |           |
| Injection drug use            | 3.86 (3.40–4.39)                     | 2.41 (2.05–2.83) | 2.28 (1.94–2.68) |
| Blood products                | 0.74 (0.60–0.90)                     | 0.79 (0.62–1.00) | 1.03 (0.75–1.43) |
| Homosexual contact            | 0.52 (0.30–0.90)                     | 0.35 (0.20–0.61) | 0.45 (0.25–0.80) |
| Unknown                       | 1.96 (1.50–2.57)                     | 1.45 (1.06–2.00) | 1.37 (0.99–1.90) |
| Type of diagnosis site        |                                      |            |           |           |
| VCT location                  | 1.00                                 | 1.00       | 1.00      |           |
| Detention center              | 3.28 (2.88–3.73)                     | 1.74 (1.51–2.01) | 1.75 (1.51–2.02) |
| Hospital/clinic               | 0.81 (0.67–0.98)                     | 0.94 (0.77–1.14) | 0.95 (0.78–1.15) |
| Blood donation station        | 0.86 (0.68–1.09)                     | 0.77 (0.63–1.29) | 0.84 (0.70–1.39) |
| Investigation                 | 1.65 (1.36–1.99)                     | 1.67 (1.37–2.03) | 0.81 (0.74–0.90) |
| Spouse/sex partner test       | 0.72 (0.52–1.01)                     | 0.66 (0.52–0.93) | 1.37 (0.95–1.90) |
| Other                         | 1.87 (1.54–2.27)                     | 1.30 (1.06–1.58) | 0.76 (0.57–1.00) |
| Location of diagnosis         |                                      |            |           |           |
| Other                         | 1.00                                 |             | 1.00      |           |
| Yunnan                        | 2.02 (1.75–2.32)                     |             | 1.61 (1.39–1.87) |           |
| Henan                         | 0.57 (0.47–0.70)                     |             | 1.06 (0.78–1.44) |           |
| Guangxi                       | 1.47 (1.23–1.76)                     |             | 1.46 (1.21–1.77) |           |
| Guangdong                     | 3.25 (2.75–3.85)                     |             | 1.94 (1.62–2.31) |           |
| Xinjiang                      | 4.19 (3.57–4.92)                     |             | 2.90 (2.09–4.02) |           |

Abbreviation: VCT, voluntary counseling and testing.

aModel included all shown variables except location of diagnosis.
bModel included all shown variables.
explained, at least in part, by a study comparing the CD4 cell counts of healthy adults of the Uygur minority group and ethnic Han Chinese, which found that those of Uygur ethnicity have significantly higher normal CD4 cell counts [40]. Although our finding of a 2.0% prevalence for the LTNP phenotype is below that reported by some, such as Madec et al [7] in France and Okulicz et al [8] in the United States, it is well above that reported by others, including Mandalia et al [9] in

| Variable                  | Unadjusted | Adjusted* | Adjustedb |
|---------------------------|------------|-----------|-----------|
| Age group, y              |            |           |           |
| ≥35                       | 1.00       | 1.00      | 1.00      |
| 25–34                     | 1.99 (1.75–2.26) | 1.60 (1.40–1.84) | 1.56 (1.36–1.79) |
| 15–24                     | 2.51 (2.17–2.90) | 2.32 (1.98–2.72) | 2.28 (1.94–2.67) |
| Sex                       |            |           |           |
| Female                    | 1.00       | 1.00      | 1.00      |
| Male                      | 1.95 (1.73–2.21) | 1.31 (1.14–1.51) | 1.28 (1.11–1.48) |
| Ethnicity                 |            |           |           |
| Han                       | 1.00       | 1.00      | 1.00      |
| Uygur                     | 1.85 (1.60–2.13) | 1.36 (1.17–1.58) | 0.73 (0.51–1.04) |
| Other                     | 0.78 (0.68–0.90) | 0.56 (0.49–0.65) | 0.60 (0.52–0.70) |
| Unknown                   | 1.43 (1.07–1.89) | 1.44 (1.01–2.07) | 1.24 (0.86–1.79) |
| Route of infection        |            |           |           |
| Heterosexual contact      | 1.00       | 1.00      | 1.00      |
| Injection drug use        | 3.07 (2.69–3.50) | 2.30 (1.95–2.71) | 2.12 (1.79–2.50) |
| Blood products            | 0.88 (1.72–1.08) | 0.91 (1.71–1.17) | 1.61 (1.14–2.28) |
| Homosexual contact        | 0.49 (0.28–0.85) | 0.35 (0.20–0.62) | 0.45 (0.25–0.80) |
| Unknown                   | 1.86 (1.41–2.46) | 1.33 (1.04–1.88) | 1.25 (0.88–1.78) |
| Type of diagnosis site    |            |           |           |
| VCT location              | 1.00       | 1.00      | 1.00      |
| Detention center          | 2.58 (2.25–2.96) | 1.63 (1.31–1.88) | 1.60 (1.39–1.86) |
| Hospital/clinic           | 1.01 (1.83–1.22) | 1.19 (0.97–1.45) | 1.14 (0.93–1.40) |
| Blood donation station    | 0.89 (1.70–1.13) | 0.91 (1.12–1.21) | 1.66 (1.26–2.19) |
| Investigation             | 1.41 (1.16–1.72) | 1.50 (1.22–1.84) | 1.52 (1.24–1.88) |
| Spouse/sex partner test   | 0.71 (1.50–0.99) | 1.17 (0.82–1.68) | 1.37 (0.96–1.97) |
| Other                     | 1.35 (1.10–1.65) | 1.13 (0.92–1.39) | 1.11 (0.90–1.37) |
| Location of diagnosis     |            |           |           |
| Other                     | 1.00       | ...       | 1.00      |
| Yunnan                    | 1.63 (1.41–1.88) | ...       | 1.52 (1.31–1.78) |
| Henan                     | 0.61 (0.49–0.75) | ...       | 0.74 (0.53–1.02) |
| Guangxi                   | 2.12 (1.76–2.55) | ...       | 2.05 (1.68–2.49) |
| Guangdong                 | 3.39 (2.84–4.05) | ...       | 2.26 (1.87–2.73) |
| Xinjiang                  | 2.81 (2.37–3.32) | ...       | 2.95 (2.08–4.18) |

Abbreviation: VCT: voluntary counseling and testing.
*Model included all shown variables except location of diagnosis.
bModel included all shown variables.

| Route of Infection | Participants, No. (%) | Uygur | All Other Ethnicities |
|--------------------|------------------------|-------|-----------------------|
| Heterosexual contact | 45 (2.9) | 1.00 | ... |
| Injection drug use | 222 (6.2) | 2.18 (1.58–3.03) | .001 | 1015 (3.4) | 3.97 (3.45–4.57) | <.001 |
| Blood products | 0 (0.0) | ... | ... | 142 (0.7) | 0.83 (0.67–1.02) | .08 |
| Homosexual contact | 0 (0.0) | ... | ... | 13 (0.5) | 0.58 (0.33–1.01) | .06 |
| Unknown | 4 (2.0) | 0.67 (0.24–1.90) | .46 | 62 (1.9) | 2.20 (1.66–2.91) | <.001 |

Abbreviations: CI, confidence interval; OR, odds ratio.
the United Kingdom. However, it is likely that differences in prevalence are attributable, at least in part, to varying definitions of LTNP and study design, and as such, these differences may not represent meaningful interpopulation variability [5, 6]. Nevertheless, the study of this rare phenotype is important because discovery of variations in host and viral factors associated with long-term nonprogression of HIV infection further our understanding of HIV biology and could be invaluable to the development of next-generation prevention and treatment strategies [1–6, 17].

The large size and nationwide scope of our cohort were important strengths of our study. However, results should be interpreted with caution, because our study had several important limitations. First, our data source had some crucial limitations, described in the Methods. Second, the retrospective cohort design precluded any examination of causality. Third, because the route of HIV infection variable relied partly on self-reporting by patients at time of diagnosis (infection route is also verified by epidemiologists during routine case investigation), social desirability and recall bias may have led to misclassification of participants and therefore overrepresentation or underrepresentation of exposures. Fourth, we did not have access to the dates, or even estimated dates, of infection or seroconversion and had to rely on dates of diagnosis instead. Although it is likely that LTNP prevalence was underestimated as a result, because the seroconversion date always preceded the diagnosis date, this may have also caused some lead-time bias because PLWH with earlier diagnoses may have had increased opportunity to be categorized as LTNP.

However, we found that median follow-up time was similar between LTNP and non-LTNP (11.0 vs 8.8 PYs) and between those reporting the IDU infection route and those reporting all other routes (8.9 [IQR, 6.9–10.8] vs 8.8 [7.5–10.7] PYs; data not shown). Furthermore, when we conducted the subanalysis using only those with HIV diagnosed “early” (ie, when the baseline CD4 cell count was still ≥500/μL), our finding of overrepresentation of the IDU route of infection among LTNP and greater odds of LTNP status among those who reported IDU as their infection route did not change. However, when we conducted the crossover stratified analyses using binary logistic regression, we found that the IDU route of infection was a robust predictor of LTNP status.

In conclusion, we provide a first-ever characterization of a nationwide cohort of 1749 LTNP in China who have remained

---

| Route of Infection and Ethnicity | Participants Aged 15–24 y |  | Participants Aged 25–34 y |  | Participants Aged ≥35 y |  |
|---------------------------------|---------------------------|----------------|---------------------------|----------------|---------------------------|----------------|
|                                 | No. (%) OR (CI) PValue    |               | No. (%) OR (CI) PValue    |               | No. (%) OR (CI) PValue    |               |
| Heterosexual contact            |                           |               |                           |               |                           |               |
| Injection drug use              | 97 (1.8) 1.00 ...         |               | 135 (1.1) 1.00 ...        |               | 59 (0.5) 1.00 ...          |               |
| Blood products                  | 395 (6.4) 3.64 (2.90–4.57) <.001 |               | 705 (3.6) 3.33 (2.77–4.01) <.001 |               | 173 (2.0) 4.26 (3.17–5.74) <.001 |               |
| Homosexual contact              | 3 (0.8) 0.45 (1.14–1.41) .17 |               | 64 (1.3) 1.16 (1.86–1.57) .32 |               | 75 (0.5) 1.11 (1.79–1.56) .55 |               |
| Unknown                         | 4 (0.5) 0.28 (1.00–3.90) .01 |               | 9 (0.9) 0.79 (0.40–1.55) .49 |               | 0 (0.0) 0.92 (0.00–1.88) ... |               |

Abbreviations: CI, confidence interval; OR, odds ratio.

Table 5. Investigation of Potential Confounding Bias: Results of Binary Logistic Regression Evaluating Route of Infection Versus Ethnicity in a Nationwide Cohort (China, 1989–2016)
AIDS-free for ≥8 years without treatment. Our finding of overrepresentation of the IDU route of infection among LTNPVs, while seemingly contradicting a large literature that supports opioids as an accelerator of HIV disease progression, makes sense in light of the spatiotemporal development of China’s HIV epidemic among PWID and suggests that perhaps a unique genetic characteristic of the viral strains circulating among the PWID population in China could be a driver of long-term nonprogression. However, both viral and host factors are known to play a role in determining the rate of HIV disease progression. Nevertheless, this unique cohort of LTNPVs in a setting where viral genetic diversity is very high warrants further study because it could point to new paths toward the advancement of HIV treatment and prevention.

Acknowledgments

The authors thank Sarah Robbins and Jeffrey Joy for their comments on manuscript development.

Author contributions. J. H. and Z. W. contributed to conceptualization and study design. J. H. conducted the primary analysis under the supervision of Z. W. All authors contributed to results interpretation. J. H., Z. W., and J. M. M. drafted the manuscript. All authors participated in many revisions of the manuscript.

Disclaimer. The views and opinions expressed herein belong to the authors alone, and do not represent the official policy, or endorsement of their affiliated institutions.

Financial support. This work was supported by the National Health and Family Planning Commission of the People’s Republic of China (grants 2018ZX10721102 and 131-16-000-105-01).

Potential conflicts of interest. J. S. G. M. has received research support from the Public Health Agency of Canada, the British Columbia Ministry of Health, the Canadian Institutes of Health Research, and the US National Institutes of Health (grants NIDA R01DA036307 and CTN 248), as well as grants to his institution by Johnson & Johnson, Merck, and Gilead. All other authors report no potential conflicts. The authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1. Pantaleo G, Fauci AS. Immunopathogenesis of HIV infection. Annu Rev Microbiol 1996; 50:825–54.
2. Poropatich K, Sullivan DJ Jr. Human immunodeficiency virus type 1 long-term non-progressors: the viral, genetic and immunological basis for disease non-progression. J Gen Virol 2011; 92:247–68.
3. Gaardbo JC, Hartling HJ, Gerstoft J, Nielsen SD. Thirty years with HIV infection-nonprogression is still puzzling: lessons to be learned from controllers and long-term nonprogressors. AIDS Res Treat 2012; 2012:161584.
4. Langford SE, Ananworanich J, Cooper DA. Predictors of disease progression in HIV infection: a review. AIDS Res Ther 2007; 4:11.
5. Gurdasani D, Iles L, Dillon DG, et al. A systematic review of definitions of extreme phenotypes of HIV control and progression. AIDS 2014; 28:149–62.
6. Sabin CA, Lundgren JD. The natural history of HIV infection. Curr Opin HIV AIDS 2013; 8:311–7.
7. Madec Y, Boufassa F, Avettand-Fenoel V, et al; ANRS SEROCO/HEMOCO Study Group. Early control of HIV-1 infection in long-term nonprogressors followed since diagnosis in the ANRS SEROCO/HEMOCO cohort. J Acquir Immune Defic Syndr 2009; 50:19–26.
8. Okulicz JF, Marconi VC, Landrum ML, et al; Infectious Disease Clinical Research Program (IDCRP) HIV Working Group. Clinical outcomes of elite controllers, viremic controllers, and long-term nonprogressors in the US Department of Defense HIV natural history study. J Infect Dis 2009; 200:1714–23.
9. Mandalia S, Westrop SJ, Beck EL, et al. Are long-term non-progressors very slow progressors? insights from the Chelsea and Westminster HIV cohort, 1988–2010. PLoS One 2012; 7:e29844.
10. Grabar S, Selingier-Leneman H, Abgrall S, et al. Prevalence and comparative characteristics of long-term nonprogressors and HIV controller patients in the French Hospital Database on HIV. AIDS 2009; 23:1163–9.
11. Ashton LJ, Carr A, Cunningham PH, et al; Investigators of the Canadian HIV+ Slow Progressor Cohort. Proinflammatory isoforms of IL-32 as novel and robust biomarkers for control failure in HIV-infected slow progressors. Sci Rep 2016; 6:23962.
12. Casado C, Pernas M, Sandonis V, et al. Identification of a cluster of HIV-1 controllers infected with low replicating viruses. PLoS One 2013; 8:e77663.
13. Cao Y, Qiu L, Zhang L, et al. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med 1995; 332:201–8.
14. Geretti AM. HIV-1 subtypes: epidemiology and significance for HIV management. Curr Opin Infect Dis 2006; 19:1–7.
15. Hao Y, Bai G, Wang J, et al. Identifiable biomarker and treatment development using HIV-1 long term non-progressor sera. BMC Immunol 2015; 16:25.
18. He X, Xing H, Ruan Y, et al. Group for HIV Molecular Epidemiologic Survey. A comprehensive mapping of HIV-1 genotypes in various risk groups and regions across China based on a nationwide molecular epidemiologic survey. PLoS One 2012; 7:e47289.

19. Mao Y, Wu Z, Poundstone K, et al. Development of a unified web-based national HIV/AIDS information system in China. Int J Epidemiol 2010; 39:i79–89.

20. Li A, Wu Z, Jiang Z, et al. Duration of human immunodeficiency virus infection at diagnosis among new human immunodeficiency virus cases in Dehong, Yunnan, China, 2008–2015. Chin Med J (Engl) 2018; 131:1936–43.

21. Wu Z, Pisani E. Fulfilling a promise: universal care. In: Wu Z, ed. HIV/AIDS in China—Beyond the Numbers. Beijing, China: People's Medical Publishing House; 2016:78–99.

22. Ministry of Health Working Group on Clinical AIDS Treatment. China Free Antiretroviral Treatment Manual. 4th ed. Beijing, China: People's Medical Publishing House; 2017.

23. Yap L, Reekie J, Liu W, et al. HIV testing in re-education through labour camps in Guangxi Autonomous Region, China (a cross-sectional survey). Sex Transm Infect 2015; 91:401–6.

24. Wang L, Guo W, Li D, et al; China National HIV/AIDS Surveillance Program. HIV epidemic among drug users in China: 1995–2011. Addiction 2015; 110:20–8.

25. Banerjee A, Strazza M, Wigdahl B, et al. Role of mu-opioids as cofactors in human immunodeficiency virus type 1 disease progression and neuropathogenesis. J Neurovirol 2011; 17:291–302.

26. Kumar R, Torres C, Yamamura Y, et al. Modulation by morphine of viral set point in rhesus macaques infected with simian immunodeficiency virus and simian-human immunodeficiency virus. J Virol 2004; 78:11425–8.

27. Meijerink H, Indrati AR, Soedarmo S, et al. Heroin use in Indonesia is associated with higher expression of CCR5 on CD4+ cells and lower ex vivo production of CCR5 ligands. AIDS 2015; 29:385–8.

28. Guo CJ, Li Y, Tian S, et al. Morphine increases HIV infection of human blood mononuclear phagocytes through modulation of beta-chemokines and CCR5 receptor. J Investig Med 2002; 50:435–42.

29. Ho WZ, Guo CJ, Yuan CS, et al. Methylaltrexone antagonizes opioid-mediated enhancement of HIV infection of human blood mononuclear phagocytes. J Pharmacol Exp Ther 2003; 307:1158–62.

30. Moorman J, Zhang Y, Liu B, et al. HIV-1 gpl20 primes lymphocytes for opioid-induced, beta-arrestin 2-dependent apoptosis. Biochim Biophys Acta 2009; 1793:1366–71.

31. Steele AD, Henderson EE, Rogers TJ. Mu-opioid modulation of HIV-1 coreceptor expression and HIV-1 replication. Virology 2003; 309:99–107.

32. Wang X, Ma TC, Li JL, et al. Heroin inhibits HIV-restriction miRNAs and enhances HIV infection of macrophages. Front Microbiol 2015; 6:1230.

33. Pehrson P, Lindback S, Lidman C, et al. Longer survival after HIV infection for injecting drug users than for homosexual men: implications for immunology. AIDS 1997; 11:1007–12.

34. Jiang H, Xie N, Cao R, et al. Determinants of progression to AIDS and death following HIV diagnosis: a retrospective cohort study in Wuhan, China. PLoS One 2013; 8:e83078.

35. Tee KK, Pybus OG, Li XL, et al. Temporal and spatial dynamics of human immunodeficiency virus type 1 circulating recombinant forms 08_BC and 07_BC in Asia. J Virol 2008; 82:9206–15.

36. Takebe Y, Liao H, Hase S, et al. Reconstructing the epidemic history of HIV-1 circulating recombinant forms CRF07_BC and CRF08_BC in East Asia: the relevance of genetic diversity and phylodynamics for vaccine strategies. Vaccine 2010; 28(suppl 2):B39–44.

37. Li X, Liu H, Liu L, et al. Tracing the epidemic history of HIV-1 CRF01_AE clusters using near-complete genome sequences. Sci Rep 2017; 7:4024.

38. Meng Z, Xin R, Zhong P, et al. A new migration map of HIV-1 CRF07_BC in China: analysis of sequences from 12 provinces over a decade. PLoS One 2012; 7:e52373.

39. Kamarulzaman A, McBrayer JL. Compulsory drug detention centers in East and Southeast Asia. Int J Drug Policy 2015; 26(suppl 1):S33–7.

40. Feng Q, Du G, Yang G, et al. Investigation on T-lymphocyte subsets absolute counting and CD4+/CD8+ ratio in healthy adults of Ugyur and Han nationalities in Karamy. Int J Lab Med 2015; 36:3227–31.